Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3359

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3359
---
 prove
effective, and the WPDS platform is designed to identify these antibodies and their corresponding antigens. We believe that such antibodies
and antigens could inform the development of therapeutic and/or vaccine candidates against the particular infectious disease. Prior to
in-licensing our product candidates, the preclinical developments of the oncology, fibrosis and malaria programs described above have,
to date, been funded through grants to our licensors totaling $105.6 million.

10

The
table below summarizes our product candidate pipeline, target indications, estimated addressable patient populations, and stage of development.

Our
Team

Our
scientific co-founders and members of our board of directors are Dr. Elias and Dr. Kurtis. Our executive chairman and co-founder is Chirinjeev
Kathuria, M.D., an investor and entrepreneur who has co-founded and driven the initial public offerings, or IPOs, of companies in various
industries including healthcare Our team brings expertise in science, medicine, agile drug development,
pharma strategy, and innovation management. Collectively, members of the team have evaluated more than 3,500 innovations; been involved
in more than 80 drug discovery / development programs, 17 clinical development programs, and 8 approved drugs; have secured more than
$120 million in venture capital funding; and have been involved in the launch of 8 biotech or life sciences companies and 3 IPOs. In
addition, beyond our day-to-day leadership team, our scientific co-founders and members of our scientific advisory board and board of
directors, Dr. Elias and Dr. Kurtis, have authored or co-authored more than 350 papers, secured more than $110 million in grant funding,
and are listed as inventors in more than 50 patents.

Submission
of Matters to a Vote of Securityholders

On
March 28, 2025, we held an annual meeting of stockholders (the “Meeting”). The Inspector of Elections determined that there
were 59,790,931 represented of the 140,584,743 common shares of the Company at the meeting amounting to 42.530 % of voting shares. At
the Meeting, the Company’s stockholders approved the following proposals (with percentages relating to the number of shares voted
on each matter):

1.
Election of Directors

For
Against Abstain Broker Non-Vote

(1)
Dr. Chirinjeev Kathuria, M.D.

28,473